Coherus Oncology (CHRS) Capital Expenditures (2013 - 2025)

Coherus Oncology has disclosed Capital Expenditures across 13 years of filings, most recently posting $8.4 million for Q4 2025.

• Capital Expenditures for Q4 2025 came in at $8.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was -$470.3 million (down 106.43% YoY), and the FY2025 annual result was -$470.3 million, down 106.43% from the prior year.
• Capital Expenditures came in at $8.4 million for Q4 2025 at Coherus Oncology, up from -$483.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $8.4 million in Q4 2025 to a low of -$483.4 million in Q2 2025.
• The 5-year median for Capital Expenditures is $206500.0 (2021), against an average of -$43.4 million.
• Across the five-year window, Capital Expenditures soared 324.14% in 2022 and plunged 123667.76% in 2024, its largest moves.
• Coherus Oncology's Capital Expenditures stood at $468000.0 in 2021, then slumped by 81.41% to $87000.0 in 2022, then tumbled by 60.92% to $34000.0 in 2023, then sank by 117747.06% to -$40.0 million in 2024, then surged by 120.94% to $8.4 million in 2025.
• The last three Capital Expenditures figures came in at $8.4 million (Q4 2025), -$483.4 million (Q2 2025), and $4.7 million (Q1 2025), per Business Quant data.